Endocrinology · 4 h ago
Phase 2 Trial Finds Weight and Glycemic Improvements With Acmopatide in Type 1 Diabetes
In a 16-week, randomized, double-blind, placebo-controlled phase 2 trial of 111 adults with type 1 diabetes and overweight or obesity, acmopatide was associated with lower HbA1c and body weight. The study was short and did not establish whether the investigational treatment offers sustained benefit or should be used in clinical practice.
- 111 adults were randomized across three doses and placebo.
- HbA1c fell 0.4–0.6 points with acmopatide.
- Weight decreased 3.3–6.7% over 16 weeks.
- No diabetic ketoacidosis or severe hypoglycemia events occurred.
Researchers randomized 111 adults with type 1 diabetes, HbA1c of 7.0–10.0% and BMI of at least 27 kg/m² to once-daily subcutaneous acmopatide at 1.8, 4.1 or 6.6 mg, or placebo, for 16 weeks. The primary endpoint was change in HbA1c; body weight and insulin dose were secondary endpoints. Mean baseline HbA1c was 7.5% and mean BMI was 34.3 kg/m².
HbA1c fell by 0.4–0.6 percentage points across acmopatide groups, compared with 0.3 points with placebo. The placebo-adjusted difference was nominally significant for 4.1 mg (−0.3 percentage points; 90% CI −0.6 to −0.1; P=0.020). Weight decreased by 3.3–6.7% with acmopatide, while it increased by 0.3% with placebo. Insulin-dose reductions relative to placebo were reported for the 4.1- and 6.6-mg doses. Adverse events were mainly gastrointestinal; no diabetic ketoacidosis or severe hypoglycemia events occurred.
These short-term phase 2 findings do not establish long-term efficacy or safety, and the abstract reports a nominal result for the primary endpoint at one dose. The study provides no basis to change treatment practice; larger and longer trials would be needed to assess clinical benefit and risks.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Diabetes Care: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.